Intensity Therapeutics Inc. (NASDAQ:INTS) Short Interest Down 58.0% in July

Intensity Therapeutics Inc. (NASDAQ:INTS) was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 68,355 shares, a decrease of 58.0% from the July 15th total of 162,597 shares. Based on an average trading volume of 23,378 shares, the days-to-cover ratio is presently 2.9 days. Currently, 2.7% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Several analysts have commented on INTS shares. Citigroup reiterated a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.50.

Intensity Therapeutics Stock Up 1.4%

INTS traded up $0.06 on Monday, hitting $4.01. 2,058 shares of the company were exchanged, compared to its average volume of 43,196. The stock’s fifty day moving average is $4.25 and its 200-day moving average is $5.52. Intensity Therapeutics has a 12 month low of $3.51 and a 12 month high of $43.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. The company has a market cap of $13.09 million, a PE ratio of -0.70 and a beta of 2.76.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24). Equities research analysts predict that Intensity Therapeutics will post -2.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of Intensity Therapeutics in the 4th quarter valued at approximately $26,000. Corient Private Wealth LLC bought a new position in Intensity Therapeutics in the fourth quarter valued at approximately $41,000. State Street Corp raised its position in Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after purchasing an additional 121,700 shares in the last quarter. Legacy Advisors LLC bought a new stake in Intensity Therapeutics during the fourth quarter worth $63,000. Finally, Mesirow Financial Investment Management Inc. boosted its holdings in shares of Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after purchasing an additional 51,000 shares in the last quarter. Institutional investors and hedge funds own 3.74% of the company’s stock.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.